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Pulmonary arterial hypertension (PAH) is a rare and progressive disease of the pulmonary arterial circulation that is
characterized by a progressive rise in pulmonary vascular resistance, eventually leading to right-heart failure and
death. There are currently 3 classes of drugs approved for the treatment of PAH: prostacyclin analogues, endothelin
receptor antagonists, and phosphodiesterase type 5 inhibitors. All of these therapies have been approved for use on
the basis of relatively small, short-term studies, yet it is common for each to be administered (alone or in combina-
tion) over the lifetime of a patient with PAH. Very few prospective, well-controlled PAH studies have examined long-
term clinical outcomes associated with current medical therapy. Therefore, data that support the long-term therapeu-
tic benefits of these long-term PAH therapies are limited and derived primarily from uncontrolled, observational
studies. In this perspective, the authors review the published research to assess the strengths and weaknesses of the
data that support the long-term clinical benefit of current PAH therapies. The authors conclude that current medical
therapies approved for the treatment of PAH can provide sustained benefits in hemodynamic function and exercise
capacity. The cumulative evidence, in the form of meta-analysis and registry data, suggest that patients are living lon-
ger compared with untreated patients; the reasons are likely multifactorial. Although definitive evidence will require
randomized and properly controlled long-term trials, the current evidence supports the long-term use of these drugs
for the treatment of patients with PAH. (J Am Coll Cardiol 2011;57:1053–61) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.020Pulmonary arterial hypertension (PAH) is a disease of the
pulmonary circulation that is characterized by a progressive
rise in pulmonary artery pressure and pulmonary vascular
resistance, with limited dysfunction of the left ventricle
(1). PAH is a disease that often manifests with clinical
symptoms such as shortness of breath and decreased
functional capacity but eventually leads to right-heart
failure and death (1).
The pathogenesis of PAH is poorly understood, and the
associated conditions that result in PAH are heterogenous
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these conditions ultimately lead to an insult to the pulmo-
nary vasculature resulting in signaling imbalances between
vasoconstrictive or proliferative (e.g., endothelin) and vaso-
dilatory or antiproliferative (e.g., prostacyclin, nitric oxide)
compounds. This imbalance is associated with the prolifer-
ation of endothelial and smooth muscle cells, as well as
components of the extracellular matrix, resulting in the
reduction and/or obliteration of luminal space in the pul-
monary vasculature (3,4). Current PAH therapies have
targeted these signaling pathways in an attempt to counter-
act these imbalances and delay or reverse the progressive
obliteration of pulmonary microvasculature.
There are currently 3 classes of drugs approved for the
treatment of PAH: prostacyclin analogues (e.g., epopros-
tenol, treprostinil, iloprost), endothelin receptor antagonists
(e.g., ambrisentan, bosentan, sitaxsentan [sitaxsentan is only
approved outside the U.S.*]), and phosphodiesterase type 5
inhibitors (e.g., sildenafil, tadalafil) (5,6). Considering the
*Recent reports of 2 cases of fatal hepatotoxicity with sitaxsentan, possibly related to
an idiosyncratic risk of liver injury, have led to drug withdrawal. Clinical trials
worldwide will be discontinued, and drug development for sitaxsentan in the U.S. is
no longer being pursued (6).
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PAH, as well as the limited pop-
ulation of patients with this dis-
ease, nearly all of the current
therapies were approved on the
basis of relatively small (e.g.,
500 patients) short-term stud-
ies of 12 to 24 weeks in duration
(5). Very few PAH studies have
examined long-term clinical out-
comes and efficacy measures us-
ing prospective, well-controlled
designs. Therefore, data that support the durability of
response and long-term therapeutic benefits of these long-
term PAH therapies are limited and are derived primarily
from uncontrolled, observational studies that are often
reported using post hoc analyses, subgroup comparisons,
and historical controls (Table 1) (7–26).
The purpose of this review is to evaluate the strengths and
weaknesses of current PAH therapies. We accomplish this
by critically reviewing the data from the published research
that support the long-term clinical benefit of these thera-
pies, excluding economic considerations. Data are presented
descriptively, without the inclusion of statistical tests, with a
focus on 3 key end points—exercise capacity, hemodynamic
Abbreviations
and Acronyms
IPAH  idiopathic
pulmonary arterial
hypertension
NIH  National Institutes
of Health
PAH  pulmonary arterial
hypertension
6MWD  6-min walking
distance
Summary of Long-Term Clinical Trials in PAHTable 1 Summary of Long-Term Clinical Trials in PAH
First Author (Ref. #) Active Drug
Galie et al. (12) Ambrisentan Multicenter, open-label,
Oudiz et al. (16) Ambrisentan Multicenter, open-label,
Blalock et al. (18) Ambrisentan Single-center, open-labe
Sitbon et al. (13) Bosentan Multicenter, open-label,
McLaughlin et al. (19) Bosentan Multicenter, open-label,
mean follow-up of 2.1
Sitbon et al. (20) Bosentan Multicenter, open-label,
BREATHE-1 with histo
Denton et al. (14) Bosentan Multicenter, open-label,
mean follow-up of 1.6
Provencher et al. (9) Bosentan Single-center, open-labe
Denton et al. (21) Bosentan Multicenter, open-label,
Benza et al. (22) Bosentan/sitaxsentan Multicenter, open-label,
Rich et al. (23) CCB Single-center, open-labe
maximal follow-up of
Sitbon et al. (24) CCB Single-center, open-labe
high-dose CCBs; mea
Barst et al. (25) Epoprostenol Multicenter, open-label s
McLaughlin et al. (17) Epoprostenol Single-center, open-labe
Sitbon et al. (10) Epoprostenol Single-center, open-labe
Kuhn et al. (7) Epoprostenol Single-center, open-labe
Galie et al. (11) Sildenafil Multicenter, open-label,
Galie et al. (15) Tadalafil Multicenter, open-label,
Barst et al. (26) Treprostinil Multicenter, open-label,
eligibility criteria; mea
Lang et al. (8) Treprostinil Multicenter, open-label,
ARIES-E Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-C
Antagonist Therapy for Pulmonary Hypertension; CCB  calcium-channel blocker; CTEPH  chron
pulmonary arterial hypertension; PAH-CTD  pulmonary arterial hypertension associated with co
randomized controlled trial; STRIDE-2X  Sitaxsentan to Relieve Impaired Exercise 2X; SUPER-1  Sil
Scleroderma and Connective Tissue Diseases; WHO  World Health Organization.parameters, and survival—because these metrics were re-
ported in the majority of PAH drug studies and were
reported in a reasonably consistent manner.
Methods
Long-term clinical studies of patients with PAH that reported
analyses of cardiopulmonary hemodynamic parameters, func-
tional capacity (e.g., 6-min walking distance [6MWD]),
and/or clinical outcomes (e.g., survival) published from January
1990 to March 2010 were identified using a computer-based
search of the MEDLINE database. Studies were considered
long-term if the treatment duration was approximately 1 year
or greater. The studies identified ranged from case reports and
small single-center trials to larger multicenter investigations
that were often extensions of pivotal, short-term, randomized
controlled trials. Because small, uncontrolled datasets are often
inconclusive and highly variable, we chose to focus primarily on
multicenter studies in adult patients with PAH and included
only large, single-center reports (50 patients). A few smaller
studies were included, when they were considered to be key
publications for specific drugs and larger studies were not
available (Table 1).
This perspective review is not a meta-analysis or an
analysis of the “raw data” from each trial. Statistical methods
Description of Study
ective analysis of PAH subgroup from ARIES-E with 1 yr of data (n  280)
ctive, 2-yr study (ARIES-E) (n  383)
spective analysis of subgroup from ARIES-E; 2 yrs of follow-up (n  12)
ctive study of patients previously in Study 351; mean follow-up of 1.3 yrs (n  29)
ective analysis of IPAH subgroup previously in Study 351 and BREATHE-1;
 169)
ective comparison of WHO class III IPAH subgroup previously in Study 351 and
poprostenol cohort; maximal follow-up of 3 yrs (n  139)
ective analysis of PAH-CTD subgroup previously in Study 351 and BREATHE-1;
 64)
spective study of consecutive IPAH patients; mean follow-up of 2 yrs (n  103)
ctive study in patients with PAH-CTD (TRUST); median follow-up of 0.9 yrs (n  53)
ctive, 1-yr study (STRIDE-2X); bosentan (n  84) and sitaxsentan (n  92)
of IPAH patients who were considered acute responders to high-dose CCBs;
n  64)
pective study of IPAH patients who were considered acute responders to
-up of 7.0 yrs (n  70)
f patients previously in 8-week RCT; maximal follow-up of 5.8 yrs (n  18)
of consecutive IPAH patients; mean follow-up of 3 yrs (n  162)
of IPAH patients; mean follow-up of 2.2 yrs (n  178)
of consecutive IPAH patients; maximal follow-up of 7 yrs (n  91)
ective analysis of PAH subgroup from SUPER-1 study with 1 yr of data (n  259)
ective analysis of PAH subgroup from PHIRST study with 1 yr of data (n  357)
ective study of patients from 3 RCTs, as well as de novo patients meeting
w-up of 1.6 yrs (n  860)
ective study of patients with PAH or CTEPH; mean follow-up of 2.2 yrs (n  122)
d, Multicenter, Efficacy Studies; BREATHE-1 Bosentan: Randomized Trial of Endothelin Receptor
boembolic pulmonary hypertension; IPAH  idiopathic pulmonary arterial hypertension; PAH 
e tissue disease; PHIRST  Pulmonary Arterial Hypertension and Response to Tadalafil; RCT retrosp
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(often combining multiple studies or exploring specific
subgroups in a post hoc manner), and without raw data, we
could not assess the risk for improper reporting and missing
data. Therefore, this clinical perspective presents the data
descriptively, without the inclusion of statistical tests.
Results
Description of long-term studies. The long-term PAH
trials included in this review are summarized in Table 1.
he analyses for these trials generally fall into 3 categories:
Figure 1 Change in 6MWD From Baseline Over Time in
the Beraprost 1-Year Placebo-Controlled Study
BPS  beraprost sodium; 6MWD  6-min walking distance; m  meters.
Adapted, with permission, from Barst et al. (27).
Long-Term Effects of Currently Approved PAH Therapies on CardiopTable 2 Long-Term Effects of Currently Approved PAH Therapie
First Author (Ref. #) Active Drug
Number of
Patients
in Study
Duration of Treatm
(Number of Patients in
Blalock et al. (18) Ambrisentan 12 2 yrs of monotherapy (n  11
Sitbon et al. (13) Bosentan 29 1.2 0.3 yrs (n  11)
Provencher et al. (9) Bosentan 103 1 yr of monotherapy (n  48)
Rich et al. (23) CCBs 64 3.3 1.6 yrs, acute responde
Sitbon et al. (24) CCBs 70 1.2 0.9 yrs, long-term respo
Barst et al. (25) Epoprostenol 18 1 yr (n  14) vs. baseline (n 
McLaughlin et al. (17) Epoprostenol 162 1.4 1.2 yrs (n  115)
Sitbon et al. (10) Epoprostenol 178 1 yr (n  107)
Kuhn et al. (7) Epoprostenol 91 1 yr (n  57)*Data are expressed as mean  SD. *Mean  SD derived from data in publication. †Cardiac output (l/m
mPAP  mean pulmonary artery pressure; mRAP  mean right atrial pressure; PVR  pulmonary vas) single-center retrospective studies; 2) multicenter, pro-
pective extension studies of previous short-term controlled
rials; and 3) post-hoc subgroup analyses that combined
ata from several long-term trials. All of these trials used
pen-label, observational designs. In fact, the only long-
erm, placebo-controlled PAH trial conducted to date was
or the oral prostacyclin analogue beraprost (27). In this
-year study, improvements compared with placebo (and
aseline) were observed for several clinical end points after 3
o 6 months of beraprost therapy, but these improvements
ere not maintained at later time points (e.g., 6MWD)
Fig. 1). Despite an increase in 6MWD in this study at 12
eeks, there was no improvement in hemodynamic param-
ters, which may have been an important harbinger of a lack
f efficacy with this beraprost formulation. Beraprost is not
pproved for the treatment of PAH in the U.S. or European
nion, in part because of this lack of improvement, under-
coring the risks of extrapolating results from short-term
tudies to long-term use. Therefore, although it remains the
ongest placebo-controlled PAH trial conducted to date, the
esults of this study are not included in the summary tables.
Most studies reported a mean study drug exposure time
f 1 to 3 years, although a few of the earlier studies with
alcium-channel blockers and epoprostenol followed pa-
ients for substantially longer periods (Table 1). Of note,
ost of the long-term studies only reported data for patients
ho continued to provide assessments at the later time
oints (Tables 2 and 3). Therefore, these “observed case”
ata likely represented biased, responder populations and
ust be interpreted with caution, because these data may be
iased in favor of the therapy under study.
nary Hemodynamic ParametersCardiopulmonary Hemodynamic Parameters
sis) Time Point
mPAP
(mm Hg)
Cardiac Index
(l/min/m2)
PVR
(Wood Units)
mRAP
(mm Hg)
Baseline 61 16 2.2 1.0† 12.6 5.5 9 6
Post-baseline 52 14 2.4 0.5† 9.5 4.4 9 5
Baseline 61 4 2.2 0.2 13.1 0.7 11 2
Post-baseline 57 4 2.6 0.2 10.8 0.8 9 2
Baseline 60 11 2.3 0.5 15.8 5.0‡ 8 4
Post-baseline 57 11 2.6 0.6 13.9 5.1‡ 9 5
13) Baseline 57 14 2.6 0.7 26.6 10.9§ 6 4
Post-baseline 35 13 3.6 1.1 8.7 7.5§ 6 5
(n  38) Baseline 54 10 2.8 0.6 10.3 4.6 7 4
Post-baseline 35 7 3.7 0.9 4.4 1.7 5 3
Baseline 61 15 1.9 0.6 22 11‡ 11 7
Post-baseline 54 16 2.5 0.8 14 6‡ 8 6
Baseline 61 13 1.8 0.5 16.7 6.4 13 6
Post-baseline 53 13 2.8 1.1 10.2 5.4 10 6
Baseline 68 14 1.9 0.4 37.3 10.5‡ 12 5
Post-baseline 60 12 2.5 0.5 25.0 6.9‡ 12 6
Baseline 61 15 3.6 1.0 15.9 9.9 12 7
Post-baseline 53 13 4.7 1.6 10.0 4.5 9 5
2ulmos on
ent
Analy
)*
rs (n 
nders
18)in). ‡Total pulmonary resistance (mm Hg/l/min). §PVR index (Wood units/m ).
cular resistance; other abbreviations as in Table 1.
†Media
WD 
1056 Gomberg-Maitland et al. JACC Vol. 57, No. 9, 2011
Long-Term Outcomes in Pulmonary Arterial Hypertension? March 1, 2011:1053–61Earlier clinical trials were limited to patients with primary
pulmonary hypertension or idiopathic pulmonary arterial
hypertension (IPAH) or with familial PAH or hereditary
pulmonary hypertension, whereas later trials included asso-
ciated etiologies of PAH (Table 4). This in turn led to
varied physical status on enrollment, which is important,
because it appears that PAH subgroups have different
survival rates and responses to therapies (7,8,28). Early
studies, especially with epoprostenol, focused on patients
with late-stage (New York Heart Association [NYHA]
functional class III or IV) disease. This focus was appropri-
ate at the time, considering the risks associated with this
more invasive parenteral therapy. As the field evolved
toward oral therapy, trials included larger proportions of
patients with less severe disease, resulting in study popula-
tions with primarily mild to moderate PAH symptoms
(NYHA functional class II or III). This is presumably
related to the fact that patients suitable for oral therapies
were more likely to be less sick. Differences in disease
severity for the various study populations are important, as
initial response to therapy and long-term treatment goals
may differ for patients with earlier stage disease.
More recent trials also used different clinical end points
than earlier studies with calcium-channel blockers, epopro-
stenol, and bosentan (Table 4). For these later trials, there
has been less focus on hemodynamic parameters and sur-
Long-Term Effects of Currently Approved PAH Therapies on 6MWDTable 3 Long-Term Effects of Currently Approved PAH Therapie
First Author (Ref. #) Active Drug
Number of
Patients in
Study
Duration of Treatme
(Number of Patients in An
Galie et al. (12) Ambrisentan 361 1 yr of monotherapy (n  280)
Oudiz et al. (16) Ambrisentan 383 2 yrs
2.5 mg (n  96)
5 mg (n  190)
10 mg (n  97)
Blalock et al. (18) Ambrisentan 12 2 yrs of monotherapy (n  12)
Sitbon et al. (13) Bosentan 29 9 2 months (n  19) vs. base
Denton et al. (14) Bosentan 64 1.6 0.9 yrs of monotherapy (n
Provencher et al. (9) Bosentan 103 1 yr of monotherapy (n  59)
Sitbon et al. (24) CCBs 70 5.3 3.8 yrs (n  22) vs. basel
Barst et al. (25) Epoprostenol 18 18 months (NA)
Sitbon et al. (10) Epoprostenol 178 1 yr (n  130)
Kuhn et al. (7) Epoprostenol 91 1 yr (n  25)
Galie et al. (11) Sildenafil 259 1 yr of monotherapy (n  222)
Galie et al. (15) Tadalafil 357 44 weeks (n  213)
Lang et al. (8) Treprostinil 122 4.1 to 4.5 yrs (n  122)
Data are expressed as mean  SD unless otherwise specified. *Mean (95% confidence interval).
ANOVA  analysis of variance; LOCF  last observation carried forward; NA  not available; 6Mvival and more focus on end points such as 6MWD andfunctional class. This may be due in part to the shift in study
populations toward less severe baseline symptoms and also
to the challenge of collecting invasive serial hemodynamic
parameters in patients with PAH with less severe disease.
There remains a need to find new “surrogate” markers of
survival given the poor prognosis of the patients.
Cardiopulmonary hemodynamic parameters. Hemody-
namic assessments via right-heart catheterization provide a
direct measure of disease progression relative to cardiopul-
monary function. Unlike other routine assessments in PAH
(e.g., functional class, quality of life, dyspnea), invasive
hemodynamic parameters are relatively nonsubjective and
provide a direct assessment of therapeutic response, even
when measured in observational, open-label trials. Also,
because PAH is a progressive disease that is defined by
increased cardiopulmonary dysfunction (1), hemodynamic
parameters are expected to progressively worsen relative to
baseline in untreated patients (12,29,30).
Several hemodynamic parameters have been shown to be
prognostic for long-term outcomes (31–35); therefore, sta-
bilization or improvement of cardiopulmonary hemody-
namic parameters is a fundamental goal of medical therapy
for PAH. As shown in Table 2, modest hemodynamic
improvements relative to baseline have been reported for
several PAH therapies after uncontrolled long-term treat-
ment. These improvements were most apparent for mean
6MWD
) Analysis Type 6MWD (m)
Observed data Change from baseline 39 (29 to 49)*
LOCF
Change from baseline 7 (13 to 27)*
23 (9 to 38)*
28 (11 to 45)*
Observed data Baseline 350†
Post-baseline 393†
 29) Observed data Baseline 370 17‡
Post-baseline 430 17‡
) Observed data Change from baseline 15 (11 to 40)*
Observed data Baseline 349 84
Post-baseline 390 83
 26) Observed data Baseline 380 112
Post-baseline 467 101
Observed data Baseline 264 160
Post-baseline 408 138
Observed data Baseline 253 144
Post-baseline 395 112
Observed data Baseline 296 111
Post-baseline 351 79
Observed data Change from baseline 51 (41 to 60)*
Observed data Change from baseline 38 (29 to 47)*
Repeated-measures ANOVA Baseline 305 11‡
Post-baseline 445 12‡
n. ‡Mean  SE of the mean.
6-min walk distance: other abbreviations as in Table 1.s on
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line (n
 40
ine (npulmonary artery pressure, pulmonary vascular resistance,
t
e
a
a
b
b
i
f
a
s
t
p
t
p
t
a
; FC
ance; T
1057JACC Vol. 57, No. 9, 2011 Gomberg-Maitland et al.
March 1, 2011:1053–61 Long-Term Outcomes in Pulmonary Arterial Hypertension?and cardiac index, whereas decreases in mean right atrial
pressure were relatively minimal or absent in many studies.
Because patients with PAH hemodynamically deteriorate
relative to baseline after some time point without treatment,
it is generally assumed that these long-term improvements
provide reasonable evidence of sustained hemodynamic
benefit from calcium-channel blockers, prostacyclins, and
endothelin receptor antagonists. However, nearly all of
these studies reported long-term hemodynamic results for a
subset of their original study populations, mostly those who
had not died or progressed to other treatments (i.e., “re-
sponder populations”). These data also represent group
averages, with some patients having large responses while
other did not; it is important to note, however, that few
patients had complete normalization of hemodynamic pa-
rameters or pulmonary vascular resistance. Nonetheless, the
preponderance of the evidence strongly suggests that long-
term hemodynamic function can be maintained at least in a
subset of patients who respond favorably to treatment.
Exercise capacity. Decreased exercise capacity, often with
increased dyspnea, is a hallmark symptom of PAH (1) and
an important prognostic indicator of survival in PAH
(9,10,29,36). Although change in 6MWD has been exten-
sively studied in short-term placebo-controlled trials, the
long-term durability of improvement for this end point has
been less rigorously reported. Nearly all short-term,
placebo-controlled PAH trials have demonstrated that
mean 6WMD is at or below baseline after approximately 12
to 24 weeks in untreated patients with PAH (11,12,30,37–40).
Summary of Study Populations and End Points of Long-Term ClinicaTable 4 Summary of Study Populations and End Points of Long
First Author (Ref. #) Active Drug Etiology (%)
Galie et al. (12) Ambrisentan IPAH (64), PAH-CTD (32), other
Oudiz et al. (16) Ambrisentan IPAH (63), PAH-CTD (32), other
Blalock et al. (18) Ambrisentan IPAH (92), other (8)
Sitbon et al. (13) Bosentan IPAH (83), PAH-CTD (17)
McLaughlin et al. (19) Bosentan IPAH (100)
Sitbon et al. (20) Bosentan IPAH (100)
Denton et al. (14) Bosentan PAH-CTD (100)
Provencher et al. (9) Bosentan IPAH (100)
Denton et al. (21) Bosentan PAH-CTD (100)
Benza et al. (22) Bosentan IPAH (58), PAH-CTD (30), other
Sitaxsentan IPAH (64), PAH-CTD (29), other
Rich et al. (23) CCB IPAH (100)
Sitbon et al. (24) CCB IPAH (100)
Barst et al. (25) Epoprostenol IPAH (100)
McLaughlin et al. (17) Epoprostenol IPAH (100)
Sitbon et al. (10) Epoprostenol IPAH (100)
Kuhn et al. (7) Epoprostenol IPAH (54), PAH-CTD (21), other
Galie et al. (11) Sildenafil IPAH (64), PAH-CTD (29), other
Galie et al. (15) Tadalafil IPAH (61), PAH-CTD (24), other
Barst et al. (26) Treprostinil IPAH (48), PAH-CTD (19), other
Lang et al. (8) Treprostinil IPAH (48), PAH-CTD (8), other (4
*Based on initial randomized trial, because demographic data were unavailable for the long-term
BDI Borg dyspnea index; CPET cardiopulmonary exercise testing; ECG electrocardiography
Association; QoL  quality of life; RHC  right-heart catheterization; 6MWD  6-min walking distHere, the beraprost study (27) is informative, because 6MWD efor a PAH population with functional class II or III symptoms
at baseline decreased by approximately 20 m after 12 months of
placebo treatment (Fig. 1). Thus, it reasonable that in a
symptomatic placebo group, the mean 6MWD should be at or
below baseline after a period of 1 year or more without therapy
and that long-term increases in 6MWD in treated patients
compared with baseline would provide reasonable evidence of
sustained therapeutic benefit. However, although a sustained
placebo effect over years is unlikely in patients with PAH, it
cannot be disregarded entirely.
MISSING DATA COMPLICATE ANALYSES OF LONG-TERM
6MWD DATA. Interpretation of 6MWD data from long-
erm observational trials is challenging, because treatment
ffect estimates are heavily dependent on how data are
nalyzed relative to missing values that will inevitably
ccumulate over time. In short-term trials, this issue has
een easier to address, typically with a worst-case penalty
eing applied to patients with missing data due to worsen-
ng clinical status or death (e.g., a 6MWD of 0 m is assigned
or missing post-baseline assessments) (11,12,39). This
pproach makes intuitive sense and has been reasonable for
hort-term trials for 2 reasons: 1) the short duration of these
rials limited the amount of imputed data; and 2) the same
enalty was applied to both the active and control groups, so
herapeutic benefit could be assessed relative to an untreated
opulation. For long-term, observational trials, neither of
hese criteria is met. With a fatal disease such as PAH, the
mount of missing data increases with increased drug
ls in PAHClinical Trials in PAH
NYHA Functional Class (%) Long-Term End Points Reported
I/II (40), III/IV (60)* 6MWD
I/II (46), III/IV (54) 6MWD, BDI, FC, TTCW, survival
III (100) RHC, MRI, 6MWD, survival
I (3), III (97) RHC, 6MWD, FC
I/II (9), III/IV (91) Survival
III (100) Survival
NA 6MWD, FC, survival
III (88), IV (12) RHC, 6MWD, BDI, FC, TTCW, survival
III (100) FC, TTCW, survival, QoL
I/II (42), III/IV (59) TTCW, survival
I/II (40), III/IV (60) TTCW, survival
NA RHC, FC, ECG, survival
I/II (19), III/IV (81) RHC, 6MWD, FC, survival
II (5), III (72), IV (22) RHC, 6MWD, survival
III (46), IV (54) RHC, treadmill exercise test, FC, survival
III (67), IV (33) RHC, 6MWD, FC, survival
III (52), IV (48) RHC, 6MWD, FC, survival
I/II (39), III/IV (61)* 6MWD
I/II (33), III/IV (67)* 6MWD
II (15), III (76), IV (9) Survival
II (7), III (66), IV (27) 6MWD, BDI, FC, survival
up.
functional class; MRImagnetic resonance imaging; NA not available; NYHA New York Heart
TCW  time to clinical worsening; other abbreviations as in Table 1.l Tria-Term
(4)*
(5)
(11)
(7)
(25)
(7)*
(15)*
(33)
4)
subgroxposure; therefore, treatment effect estimates are depen-
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benefit. This in itself would not be problematic if there were
an untreated control group that received the same penalty,
as the measured response could be adjusted relative to a
control group; however, this is not the case.
An alternative but perhaps equally unsatisfying approach
for the long-term assessment of 6MWD is to ignore
missing data and analyze only those values observed at a
specific time point (i.e., observed case or “responder popu-
lation” analysis). As shown in Table 3, this is the approach
taken for nearly all long-term studies to date, many of which
reported 6MWD data that excluded more than one-third of
the entire study population (7,9,13–15). This approach is
inherently biased, as it enriches for a “responder population”
that is most likely to show therapeutic benefit. Therefore,
similar to the case for hemodynamic parameters, the most
that can be concluded from these observed case analyses is
that there appears to be sustained improvement in exercise
capacity in a subpopulation of patients who remain on
long-term therapy. The strength of these conclusions and
the degree to which they can be generalized to patients in
clinical practice depends on the proportion of the study
population included in the analysis. Thus, we suggest that
the reporting of long-term observed case data should always
be accompanied with a detailed description of patients
excluded from the analysis because of death, clinical wors-
ening, adverse events, or other reasons.
Oudiz et al. (16) recently published a third approach for
handling missing long-term data in PAH trials, which has
not been previously done in other PAH trials. In this study,
patients were treated with ambrisentan for up to 2 years and
a last-observation-carried-forward method was used for the
imputation of missing 6MWD data at later time points.
The intent of this type of analysis is to capture worsening
that occurs before the discontinuation of a patient and apply
these values toward the final analysis. Although this ap-
proach allows data to be analyzed for all patients in a study,
it is not without limitations. Actual 6MWD results at a
specific time point after discontinuation (if collected) might
have been worse than the imputed last-observation-carried-
forward value, especially if the patient was left untreated.
Furthermore, this approach would not include penalties for
patients with missing data who experience an acute wors-
ening event (e.g., death) without previous decline. None-
theless, the treatment effect estimates using this last-
observation-carried-forward approach (Table 3) were more
conservative (i.e., 2- to 3-fold lower in several groups) than
an observed case analysis from the same study (Fig. 2).
INTERPRETATION OF BENEFIT ON THE BASIS OF CURRENT
LONG-TERM 6MWD DATA. Considering the different analy-
es and presentations summarized in Table 3, these long-
erm 6MWD data should not be compared. Nor should the
MWD values presented for individual studies be overem-
hasized, because they are estimates that are inherentlyinked to the analysis methods used to generate them. Yet tonsidering the progressive nature of PAH and the known
ehavior of placebo groups in short-term trials for this end
oint, the clinically relevant increases in 6MWD reported in
hese long-term studies suggest that current therapies are
apable of providing sustained improvements in exercise
apacity in patients with PAH.
urvival. Few randomized, well-controlled PAH trials
ave demonstrated a survival advantage for current medical
herapy (38,41). This may be due in part to the relatively
mall sample sizes and short durations of follow-up in these
rials, resulting in low statistical power to detect these
vents. To overcome these statistical limitations, Galie et al.
42) recently conducted a meta-analysis of more than 20
andomized, controlled short-term PAH trials (mean dura-
ion 14.3 weeks), and from these pooled data, they con-
luded that current PAH therapies were associated with a
3% reduction in mortality (relative risk: 0.57; 95% confi-
ence interval: 0.35 to 0.92). Although these results are
ncouraging, it is unclear if they support a true long-term
urvival advantage for medical therapy or if the risk reduc-
ion observed in this analysis was due to a relatively modest
elay in mortality beyond the short-term observation peri-
ds of these studies. Thus, the effects of medical therapy on
urvival must still be inferred primarily from long-term
bservational studies and historical controls.
During the 1980s, a national registry was established to
tudy the natural history of patients with primary pulmonary
ypertension (i.e., IPAH or heritable PAH) receiving no
AH-specific therapy (43). From this registry, a median
urvival of 2.8 years was reported in the overall population,
ith 1-, 3-, and 5-year survival rates of 68%, 48%, and 34%,
espectively (31). Approximately two-thirds of patients in
his registry were considered in NYHA functional class III
r IV at baseline, and these patients had considerably lower
edian survival times (2.6 and 0.5 years for NYHA func-
Figure 2 Change in 6MWD From Baseline at
2 Years in the Ambrisentan ARIES-E Study
Effect of a last-observation-carried-forward (LOCF) imputation analysis versus
an observed case analysis. ARIES-E  Ambrisentan in Pulmonary Arterial
Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Effi-
cacy Studies; 6MWD  6-min walking distance.ional classes III and IV, respectively) compared with
t al. (3
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Since that time, several reports have indicated that baseline
functional class, as well as exercise capacity and hemody-
namic parameters, are important predictors of long-term
survival (9,10,17,44–46). From the National Institutes of
Health (NIH) registry dataset, a formula was developed to
predict the risk for death for IPAH or heritable PAH and
patients with anorexigen-associated PAH on the basis of 3
baseline hemodynamic parameters (mean pulmonary artery
pressure, mean right atrial pressure, and cardiac index) (31).
As shown in Table 5, many long-term studies have compared
predicted survival on the basis of this formula to observed
survival in various IPAH populations, and in nearly every
report, the comparison has favored medical therapy. Again,
the data are encouraging and consistent with the long-term
data reported for cardiopulmonary hemodynamic parame-
ters and exercise capacity; yet, they do not constitute
definitive proof of a survival benefit.
In fact, recent data from several contemporary PAH
Long-Term Effects of Currently Approved PAH Therapies on SurvivaTable 5 Long-Term Effects of Currently Approved PAH Therapie
First Author (Ref. #) Active Drug
Number of Patients
in Study
Oudiz et al. (16) Ambrisentan 383 IPAH
oth
Sitbon et al. (13) Bosentan 29 IPAH
McLaughlin et al. (19) Bosentan 169 IPAH
Sitbon et al. (20) Bosentan 139 IPAH
Denton et al. (14) Bosentan 64 CTD (1
Provencher et al. (9) Bosentan 103 IPAH
Denton et al. (21) Bosentan 53 CTD (1
Benza et al. (22) Bosentan/sitaxsentan 84/92 IPAH
(30
Rich et al. (23) CCBs 64 IPAH
Sitbon et al. (24) CCBs 70 IPAH
Barst et al. (25) Epoprostenol 18 IPAH
McLaughlin et al. (17) Epoprostenol 162 IPAH
Sitbon et al. (10) Epoprostenol 178 IPAH
Kuhn et al. (7) Epoprostenol 91 IPAH
oth
Barst et al. (26) Treprostinil 860 IPAH
oth
Lang et al. (8) Treprostinil 122 IPAH
oth
All survival data are expressed as Kaplan-Meier estimates. Predicted survival based on D’Alonzo e
CHD  congenital heart defect; other abbreviations as in Table 1.registry studies have suggested that survival estimates aspredicted by the NIH formula may no longer be relevant
and/or accurate in the current era of PAH-directed therapy.
The Pulmonary Hypertension Connection registry evalu-
ated the long-term survival of 576 patients with PAH from
3 expert centers in Chicago who received various PAH
treatments from 1991 to 2007 (47). In the overall PAH
cohort, observed survival was 86%, 69%, and 61% at 1, 3,
and 5 years, respectively. In 247 patients with idiopathic,
familial, and anorexigen-associated PAH (i.e., etiologies
similar to those in the NIH model), observed survival was
significantly higher than NIH-predicted survival at 1 year
(92% vs. 65%), 3 years (75% vs. 43%), and 5 years (66% vs.
32%), respectively. A second, independent registry of 354
adults in France with idiopathic, familial, or anorexigen-
associated PAH who received various PAH treatments over
a period from 2002 to 2003 also observed similar 1-, 3-, and
5-year survival rates (83%, 67%, and 58%, respectively), and
these observed survival rates were approximately 10 percent-
age points higher than those predicted by the NIH formula
Survival
gy (%) Survival
AH-CTD (32), 94% and 88% at 1 and 2 yrs in overall population; 96% and 89%
at 1 and 2 years in IPAH vs. predicted survival of 72% and
61%; 91% and 83% at 1 and 2 yrs in PAH-CTD
AH-CTD (17) No patients died during the placebo-controlled period (placebo or
active) or during the long-term follow-up (1.3 0.3 yrs)
96% and 89% at 1 and 2 yrs vs. predicted survival of 69%
and 57%
97% and 91% at 1 and 2 yrs vs. 91% and 84% in a historical
cohort receiving epoprostenol
86% and 73% at 1 and 2 yrs
92%, 89%, and 79% at 1, 2, and 3 yrs vs. predicted survival of
71%, 61%, and 51%
92% at 48 weeks
), PAH-CTD
other (11/7)
96% for sitaxsentan and 88% for bosentan at 48 weeks; 95% for
sitaxsentan (n  65) and 91% for bosentan (n  58) at 48
weeks in IPAH/CHD; 96% for sitaxsentan (n  27) and 80%
for bosentan (n  25) at 48 weeks in PAH-CTD
94% at 1, 3, and 5 yrs in acute responders (n  17) vs. predicted
survival of 68%, 47%, and 38%
97% at 1, 3, and 5 yrs in long-term responders (n  38) vs. 71%,
62%, and 48% in long-term nonresponders (n  19)
87%, 63%, and 54% at 1, 3, and 5 yrs vs. predicted survival of
77%, 41%, and 27%
88%, 76%, and 63% at 1, 3, and 5 yrs vs. predicted survival of
59%, 46%, and 35%
85%, 63%, and 55% at 1, 3, and 5 yrs vs. predicted survival of
58%, 33%, and 28%
AH-CTD (21),
)
85%, 76%, and 65% at 1, 2, and 3 yrs in IPAH vs. predicted
survival of 62%, 49%, and 39%; 58%, 41%, and 34% at
1, 2, and 3 yrs in PAH-CTD
AH-CTD (19),
)
87%, 78%, 71%, and 68% at 1, 2, 3, and 4 yrs in overall
population; 91%, 82%, 76%, and 72% at 1, 2, 3,
and 4 yrs in IPAH patients vs. predicted survival
of 69%, 56%, 46%, and 38%
AH-CTD (8),
)
89%, 71%, and 66% at 1, 3 and 4 yrs; survival was similar by
etiology (IPAH, PAH-CTD, CHD, CTEPH, anorexigen use)
1).ls on
Etiolo
(63), P
er (5)
(83), P
(100)
(100)
00)
(100)
00)
(58/64
/29),
(100)
(100)
(100)
(100)
(100)
(54), P
er (25
(48), P
er (33
(48), P
er (44(46). Finally, recent analyses from a U.S.-based, multicenter
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outcomes of patients with PAH treated with various PAH-
specific drugs (the Registry to Evaluate Early and Long-
Term Pulmonary Arterial Hypertension Disease Manage-
ment) demonstrated that the NIH formula has relatively
low power (i.e., slightly better than random chance) to
discriminate between patients at high and low risk for death
at 1 year (45).
The poor performance of the NIH formula when applied
to contemporary PAH populations likely reflects important
differences in the diagnosis and treatment of PAH between
the early 1980s and the current era. Although none of the
recent registry studies specifically examined response to
therapy as a predictor of survival, several did develop new
predictive models (44,45) that include multiple risk factors
known to be modified by current medical therapy (e.g.,
6MWD, B-type natriuretic peptide, hemodynamic param-
eters, functional class). Therefore, medical therapy should
have a positive impact on survival in patients whose re-
sponse to therapy places them in a better risk category for
these models. Prospective, long-term studies will be re-
quired to test these hypotheses and the impact of specific
medical therapies on survival.
Conclusions
Published data indicate that the current medical therapy
approved for the treatment of PAH can provide sustained
benefits on hemodynamic function and exercise capacity, 2
clinical measures that help predict survival in patients with
PAH. Consistent with these data, a meta-analysis of short-
term randomized trials suggests that current medical ther-
apies decrease the risk for death in patients with PAH. In
long-term observational studies, patients with PAH receiv-
ing medical therapy have better survival rates than predicted
outcomes on the basis of untreated historical controls.
However, it is unknown whether long-term response to
current medical therapy will be similar in patients with
pulmonary hypertension due to other etiologies not previ-
ously enrolled in clinical studies. Furthermore, nearly all of
these long-term studies allowed for the addition of other
approved PAH therapies; therefore, survival rates observed
in these long-term extension trials are not due solely to the
original therapies tested in the initial short-term placebo-
controlled trials.
The present data are consistent with the conclusion that
current medical therapies provide sustained clinical benefits
in patients with PAH, yet definitive evidence will require
randomized and properly controlled long-term trials, pref-
erably with composite clinical outcome end points and/or
goal-oriented designs. Several such studies have recently
been completed or are currently under way that will com-
pare long-term treatment strategies such as first-line mono-
therapy, add-on combination therapy (e.g., Pulmonary Ar-
terial Hypertension Combination Study of Epoprostenol
and Sildenafil, Effects of the Combination of Bosentan andSildenafil Versus Sildenafil Monotherapy on Pulmonary
Arterial Hypertension), and, more important, first-line
combinations therapy (e.g., A Study of First-Line Am-
brisentan and Tadalafil Combination Therapy in Subjects
With Pulmonary Arterial Hypertension) (48–50). These stud-
ies should substantially deepen our understanding of the
long-term benefits of medical therapy in this devastating
disease. In the meantime, the current evidence supports the
long-term use of these drugs for the treatment of PAH while
the search for a curative therapeutic regimen continues.
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